Skip to main content
Medical Reference · Condition Monograph

Prostate Cancer

전립선암

A common cancer of the male prostate; with advances in diagnostic and treatment techniques, the outcome is generally favorable when it is detected early. Detecting it before symptoms appear through screening such as PSA testing is important.

History

Prostate cancer has existed for a long time, but as diagnostic technology and treatment tools have advanced, it has become "a cancer that is detected more often and treated better." In the 19th century, masses in the prostate observed at autopsy began to be recorded in the literature, and as microscopic pathology became established, malignant tumors of the prostate were defined as a separate disease. Early treatment centered on surgery to relieve the symptoms of urinary obstruction rather than to remove the cancer, and radical prostatectomy, which removes the entire prostate, gradually developed into a standard treatment as knowledge of anesthesia, bleeding control, and anatomy accumulated.

From the mid-20th century onward, as radiation equipment became more precise, it became possible to deliver radiation accurately to the prostate, and as it became known that prostate cancer cells are influenced by male hormones (androgens), hormone suppression therapy became a major pillar of treatment. It plays an important role in reducing pain and slowing disease progression in metastatic prostate cancer, and it later expanded into a variety of drug combinations.

With the introduction of the prostate-specific antigen (PSA) blood test, early detection became possible even in people without symptoms, and this brought the advantage of earlier diagnosis together with the emerging problems of overdiagnosis and overtreatment. Therefore, rather than "treating every prostate cancer immediately," a strategy developed of safely monitoring low-risk cancers through active surveillance.

Recently, diagnostic accuracy has improved with precise tests such as multiparametric magnetic resonance imaging of the prostate, MRI-targeted biopsy, and PSMA PET-CT, and as robotic surgery, high-precision radiation therapy, and targeted therapy have advanced, treatment goals have come to address not only cure but also long-term management and preservation of quality of life.

Causes

Rather than arising from one specific cause, prostate cancer develops when changes accumulate in the DNA of prostate cells over a long period and control of cell growth breaks down. Normal cells stop on their own or die when damage is severe, but in cancer cells these safety mechanisms break down, so they keep dividing and form a tumor. Therefore, it is better to understand prostate cancer not as "a disease that appears suddenly one day" but as a condition greatly influenced by age and time.

The strongest risk factor is age. It is rare at younger ages, begins to increase in the 50s, and rises sharply after the 60s. Family history is also important. The risk rises if a close family member such as a father or brother has had prostate cancer, and if several family members have the disease or were diagnosed at a relatively young age, genetic predisposition may have played a stronger role.

Differences in incidence by race and region are also reported, but these may reflect not only genetic background but also factors such as access to medical care, whether PSA screening is performed, dietary habits, and obesity rates. The key point is that prostate cancer is not "the individual's fault" but a disease that arises from various factors accumulating over a long period.

It is difficult to conclude for an individual that a particular lifestyle factor "is the cause," but obesity and lack of exercise, a high-calorie diet with a large proportion of processed meat and red meat, and smoking can act to increase overall cancer risk, so managing them is recommended.

Genetic Epidemiology

Genetic epidemiology examines in which genetic backgrounds prostate cancer is more common and how it appears within families. Prostate cancer is one of the cancers with a relatively clear family history; if a first-degree relative (father, brother, etc.) has the disease, the risk increases meaningfully. The more family members with the disease, and the younger the age at diagnosis, the greater the contribution of genetic factors may be.

Most notably, BRCA2 mutations are associated with an increased risk of prostate cancer and in some cases may also be associated with a more aggressive pattern. Mutations in genes involved in DNA damage repair, such as BRCA1, ATM, and CHEK2, are also found in some patients. In addition, genes such as HOXB13 are known to be associated with increased risk, particularly in familial prostate cancer. Because these genes are related to "the systems that repair damaged DNA or control cell division," a decline in their function can create an environment in which cancer develops more easily.

Having a genetic variant does not mean cancer will necessarily develop. From the general public's point of view, it is enough to understand that "if there is a family history or genetic risk, counseling and screening can be considered from an earlier age" and that "genetic information is used not to create fear but for tailored screening and treatment choices."

General Epidemiology

Prostate cancer is one of the most common cancers in men, and diagnosis rates and mortality rates differ greatly between countries. In countries where PSA screening is widespread, the proportion detected early is high, so the diagnosis rate tends to appear high; conversely, in regions where screening is rare, the cancer is detected at an advanced stage, so mortality may appear relatively high. In other words, "differences in occurrence itself" and "differences in how it is detected" act together.

Age is central to the epidemiology of prostate cancer. It is very rare under age 40 and increases greatly after the 60s, and in older men it is not uncommon for small cancers within the prostate to be found incidentally. This shows that, for prostate cancer, "cancer that is detected" and "cancer that threatens life" are not always the same.

Recent epidemiology and clinical practice treat overdiagnosis and overtreatment as important problems. This is because if even low-risk cancers are all treated, quality of life can drop significantly due to side effects such as urinary incontinence and decreased sexual function. Therefore, a strategy has spread of combining the PSA level, the grade group from the biopsy, MRI findings, the stage, and other information to distinguish "whether the cancer truly needs treatment," and of managing some cases with active surveillance.

Pathogenesis

Prostate cancer begins when DNA damage accumulates in normal prostate cells and the mechanisms that control that damage break down. Cancer cells keep growing and form a mass even in situations in which they would normally stop or die, and over time they can spread into surrounding tissue or metastasize to other sites through blood vessels and lymphatic vessels. In prostate cancer, metastasis to the lymph nodes and bones is especially common.

The prostate is an organ strongly influenced by male hormones (androgens such as testosterone), and prostate cancer cells also often depend on these hormone signals to grow in the early stage. Therefore, treatment that lowers male hormones or blocks their action (androgen deprivation therapy, ADT) is used as the basic treatment for metastatic prostate cancer.

During treatment, some cancer cells may "adapt" to survive even in a low-hormone environment. This is called castration-resistant prostate cancer (CRPC), and at this stage various treatments, such as stronger blockade of hormone signals, chemotherapy, targeted therapy, and radiopharmaceutical therapy, are applied step by step. Bone metastases can cause complications such as pain, fractures, and spinal cord compression, so symptoms such as persistent bone pain or leg weakness are important warning signs.

Symptoms

Prostate cancer often has no symptoms in the early stage. Therefore, many people discover it incidentally through a PSA test or similar, or are diagnosed while being tested for another reason. When symptoms appear, urinary symptoms are common, but it is difficult to distinguish cancer by these alone.

The urine stream may become weak, it may be difficult to start urinating and take a long time, or there may be a feeling that the stream stops and starts. Frequent trips to the bathroom (frequency), a sudden urgent need to urinate (urgency), and waking up several times at night (nocturia) are also common. However, because these symptoms are also very common in benign prostatic hyperplasia and prostatitis, one should not conclude that "there are symptoms, so it is cancer."

In advanced cases, blood in the urine or semen, pelvic or perineal pain, weight loss, and fatigue may appear. In particular, when bone metastases develop, pain in specific areas such as the lower back, pelvis, or ribs may persist or gradually worsen, and when spinal metastases press on nerves, neurological symptoms such as leg numbness, weakness, walking difficulties, and problems controlling urination and bowel movements may occur. These symptoms require prompt evaluation.

Signs

Signs are objective findings that medical staff confirm through testing. The most common sign is an elevated PSA (prostate-specific antigen) blood test level. Because PSA is a protein produced in the prostate, it can rise not only with prostate cancer but also with benign prostatic hyperplasia, prostatitis, urinary tract infection, recent ejaculation, and after certain procedures. Therefore, it is appropriate to understand PSA not as a confirmatory test but as "a signal indicating whether further evaluation is needed."

On digital rectal examination, feeling a hard nodule, asymmetry, or an irregular surface is a suspicious sign. As an imaging test, multiparametric magnetic resonance imaging of the prostate (mpMRI) helps find suspicious lesions and estimate the likelihood of clinically significant cancer. The higher the PI-RADS (Prostate Imaging Reporting and Data System) score on MRI, the greater the likelihood of significant cancer.

The definitive sign is the confirmation of cancer cells on prostate biopsy. The pathology results include the Gleason score and grade group to judge the aggressiveness of the cancer. In addition, if lymph node or bone metastases are confirmed on CT, MRI, bone scan, PSMA PET-CT, or similar tests, the stage becomes higher and the treatment strategy changes greatly.

Screening

Screening is testing to detect prostate cancer early in people without symptoms. The core is the PSA blood test, and in some cases a digital rectal examination is also considered. A high PSA does not immediately confirm cancer, but it indicates increased risk and serves as the basis for deciding whether to perform further tests (repeat testing, MRI, biopsy).

PSA can fluctuate temporarily in various situations. Because it can rise with prostatitis or urinary tract infection, recent ejaculation, strenuous exercise or bicycle riding, and after prostate massage or procedures, an ambiguous elevation may be retested after a certain period or reevaluated after treating inflammation. In addition, drugs for benign prostatic hyperplasia (5α-reductase inhibitors) can lower PSA, so if you are taking them, the interpretation must be adjusted.

The advantage of screening is that it can detect prostate cancer that needs treatment early. The disadvantage is that it can also detect cancers that grow slowly and would never cause problems in a lifetime, so quality of life may be reduced by unnecessary biopsies or treatment. Therefore, an approach of deciding on screening after counseling that takes into account age, life expectancy, family history, individual risk, and one's own values is recommended.

Diagnosis

The diagnosis of prostate cancer proceeds in the sequence "suspicion → confirmation → staging." First, if there is a PSA elevation or an abnormal digital rectal examination, multiparametric magnetic resonance imaging of the prostate (mpMRI) is often performed to identify the location and extent of suspicious lesions. mpMRI shows areas with a high likelihood of clinically significant cancer and also allows some estimation of the likelihood that the cancer has spread beyond the prostate.

Confirmation is made by prostate biopsy. Usually, a systematic biopsy that takes tissue from several areas of the prostate under ultrasound guidance is performed, and if necessary, a targeted biopsy aimed at lesions seen on MRI is performed at the same time. The approach can be transrectal or transperineal and is chosen in consideration of infection risk and the patient's condition.

When cancer is confirmed on biopsy, its aggressiveness is judged by the Gleason score/grade group, and the risk group is classified using the PSA level and clinical stage together. For staging, depending on the risk level, the lymph nodes are checked with CT/MRI, and if bone metastasis is suspected, a bone scan or PSMA PET-CT, among others, is considered. The information obtained in this way is combined to set the treatment goal (cure, suppression of progression, symptom relief).

Treatment

Treatment of prostate cancer depends on the stage (degree of spread) and risk level (aggressiveness), as well as the individual's life expectancy, coexisting conditions, and priorities regarding quality of life. Some low-risk prostate cancers confined to the prostate grow very slowly and may never cause problems in a lifetime, so active surveillance is an important option. This is not postponing treatment but an approach of regularly performing PSA tests, examinations, MRI, repeat biopsies, and so on, and switching to treatment immediately if changes occur.

The representative radical treatments aimed at cure are surgery and radiation therapy. Surgery (radical prostatectomy) removes the prostate and surrounding tissue, and there are open, laparoscopic, and robotic approaches. Radiation therapy includes external beam radiation therapy and brachytherapy, and hormone therapy is sometimes combined depending on the risk group. The two treatments often have similar cancer control outcomes, but surgery can cause urinary incontinence and decreased erectile function, while radiation therapy can cause irritative urinary and bowel symptoms and rare rectal complications, so a choice tailored to the individual's situation is needed.

When the cancer has spread beyond the prostate or has metastasized, androgen deprivation therapy (ADT) is the center of treatment. Depending on the condition, a strategy of combining anticancer drugs (e.g., docetaxel) or newer hormonal agents (e.g., abiraterone, enzalutamide) from the start is used to prolong survival. At the castration-resistant stage, when the response to hormone therapy declines, sequential use of drugs, chemotherapy, treatment of bone metastases, radiopharmaceutical therapy, pain management, and other measures are carried out in an integrated manner.

Prognosis

The prognosis of prostate cancer differs greatly depending on the stage and risk level at diagnosis. Many patients are diagnosed while the cancer is confined to the prostate, and in these cases long-term survival rates are very high, so it is often classified as a "treatable cancer." Conversely, aggressive cancers that have metastasized or have a high grade group make treatment more complex and can have a worse prognosis.

In judging prognosis, the PSA level, the Gleason score/grade group, the stage confirmed by imaging, and changes in PSA after treatment are important. After surgery, PSA generally falls to nearly 0, and if it rises again afterward, the possibility of recurrence is evaluated. After radiation therapy, PSA falls gradually, and if there is a sustained rise beyond a certain threshold, recurrence or progression is considered.

Recently, as treatment options have diversified, even metastatic prostate cancer is increasingly managed longer and more stably than in the past. The important messages for the general public are that "the earlier it is detected, the better the prognosis," that "regular follow-up is key even after treatment," and that "not only survival but also management of quality of life, such as urinary function, sexual function, and bone health, is important for long-term prognosis."

Prevention

To date, no single method (vaccine or definitive preventive drug) that reliably prevents prostate cancer has been clearly established. Therefore, it is realistic to think of prevention in two parts: increasing the likelihood of lowering risk through overall healthy habits, and establishing an early detection strategy tailored to individual risk.

In terms of lifestyle, maintaining an appropriate weight and exercising regularly are important. Because obesity and metabolic diseases can raise the risk of many chronic diseases and cancers, weight management itself benefits not only prostate cancer risk but overall health. For diet, a balanced pattern centered on vegetables, fruits, whole grains, legumes, and fish is often recommended, and reducing red meat, processed meat, and excessive calorie intake may help.

Drug-based prevention is complicated to interpret. There are studies showing that 5α-reductase inhibitors used to treat benign prostatic hyperplasia can lower the rate of prostate cancer diagnosis, but the long-term benefits and risks must be weighed for each individual. Therefore, rather than starting the drug solely for prevention, it is reasonable to consult medical staff when treatment for benign prostatic hyperplasia is needed.

An early detection strategy is especially important for people with a family history or genetic risk. It helps to understand the pros and cons of PSA screening and to decide when to start testing and how often to test according to one's age, health status, and life expectancy. Conversely, if a person is elderly or has a limited life expectancy, the benefit of testing may be small, so avoiding unnecessary tests and treatment is also part of "realistic prevention."

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.